bluuebunny/crossref_metadata_2025_split huggingface dataset:
An asymmetric synthesis of duloxetine hydrochloride, a mixed uptake inhibitor of serotonin and norepinephrine, and its C‐14 labeled isotopomers
Authors: Wheeler William J. , Kuo Fengjiun 
Published: October 2006

AbstractTwo 14C‐isotopomers of duloxetine HCl (S‐(+)‐N‐methyl‐3(1‐naphthal‐ enyloxy)‐3(2‐thiophene)propanamine hydrochloride), a potent mixed serotonin/norepinephrine uptake inhibitor have been prepared by an asymmetric synthesis. The palladium catalyzed cross‐coupling of 2‐thienoyl chloride (3c) (or its [carbonyl‐14C] isotopomer 3d) with vinyl tri‐n‐butylstannane, followed by addition of HCl afforded the key pro‐chiral intermediate chloroketone (5a, b). Chiral reduction with borane in the presence of the appropriate oxazaborolidine catalyst (14a or b) provided the S‐chloroalcohol (7a) and its 14C‐labeled counterpart 7b or the analogous R‐chloroalcohol (6). Activation of 7a, b by reaction with NaI/ acetone, followed by reaction of the corresponding iodoalcohol with methylamine yielded the penultimate aminoalcohols (8a, b). Formation of the alkoxide with NaH, followed by reaction with 1‐fluoronaphthalene yielded duloxetine or its 14C‐labeled isotopomer 9. Alternatively, reaction of 6 with 1‐naphthol‐[1‐14C] under Mitsunobu conditions afforded arylether 10a, b, which was in turn activated by reaction with NaI/acetone. Subsequent reaction of 10c, d with methylamine followed by salt formation yielded duloxetine or its naphthalene‐labeled isotopomer (13) as their HCl salts.
Site‐specific labelling of caged atp with deuterium or 18oxygen
Authors: Corrie John E. T. , Reid Gordon P. 
Published: October 2006

Abstract[3‐D]2‐Nitroacetophenone and [alcohol‐18O]‐1‐(2‐nitrophenyl)ethyl alcohol were prepared and used to synthesise labelled P3‐l‐(2‐nitrophenyl)ethyl esters of ATP (“caged ATP”) with isotope present either as deuterium on the 3‐position of the nitrosubstituted ring or as 18oxygen in the bridging position between the terminal phosphate and the nitrophenylethyl group. The availability of the deuterated compounds enabled complete assignment of their 1H NMR spectra.
Preparation of 1‐methyl‐4‐[4‐(7‐chloro‐4‐quinolyl‐[3‐14C]‐amino)benzoyl]piperazine
Authors: Wang Theodore S. T. , Fawwaz Rashid A. , Van Heertum Ronald L. 
Published: October 2006

Abstract1‐Methyl‐4‐[4‐(7‐chloro‐4‐quninolyl‐[3‐14C]amino)‐benzoyl]piperazine (V) was prepared for pharmacokinetic and pharmacodynamic evaluation. The synthesis of V was accomplished first by a modified Claisen ester condensation reaction of diethyl‐[2‐14C]‐malonate, triethyl orthoformate, and acetic anhydride in the presence of ZnCl2 to form ethyl ethoxymethylene‐[2‐14C]‐malonate (I), which was further condensed with m‐chloroaniline to yield 7‐chloro‐4‐hydroxy‐3‐[14C]‐quinoline‐ethylcarboxylate (II). Saponification of II yielded the corresponding carboxylic acid (III). Decarboxylation of the acid group upon heating and a substitution of the 4‐OH group of compound III into chlorine atom with POCl3 produced 4,7‐dichloro‐[3‐14C]‐quinoline (IV), which then was reacted with 1‐methyl‐4‐(pamino‐benzoyl)piperazine to form the title compound V. There were a total of five steps of reaction, with a overall yield of 34.3%. The specific activity was 1.74 mCi/mmol.
Synthesis of 1,2,3‐trideutero amines, alcohols and hydrocarbons from tricarbonyliron(0) complexes of 1‐heterodienes and homodiens
Authors: Danks Timothy N. 
Published: October 2006

AbstractA simple procedure for the synthesis of 1,2,3‐trideutero amines, alcohols and hydrocarbons from the reaction between lithium aluminiumdeuteride and tricarbonyliron(0) complexes of 1‐heterodienes and homo‐dienes is reported.
No‐carrier‐added (NCA) synthesis of 6‐[18F]fluoro‐L‐DOPA using 3,5,6,7,8,8a‐hexahydro‐7,7,8a‐trimethyl‐[6s‐(6α,8α,8αβ)]‐6,8‐methano‐2H‐1,4‐benzoxazin‐2‐one
Authors: Horti Andrew , Redmond D. Eugene , Soufer Robert 
Published: October 2006

Abstract3,5,6,7,8,8a‐Hexahydro‐7,7,8a‐trimethyl‐[6S‐(6α,8α,8αβ)]‐6,8‐methano‐2H‐1,4‐benzoxazino‐2‐one (2) was investigated as chiral auxiliary for asymmetric NCA nucleophilic synthesis of 6‐[18F]Fluoro‐L‐DOPA. Direct condensation of 3,4‐dimethoxy‐2‐[18F]fluorobenzaldehyde (1a) or 6‐[18F]fluoropiperonal (1b) in the presence of NaH with 2 gave the corresponding [18F]‐3‐[(2‐fluorophenyl)methylene]‐3,5,6,7,8,8a‐hexahydro‐7,7,8a‐trimethyl‐[6S‐(3Z,3α,6α,8α,8αβ)]‐6,8‐methano‐2H‐1,4‐benzoxazin‐2‐one derivative 3a or 3b as a single stereoisomer. L‐Selectride® promoted hydrogenation of the olefinic double bond of these derivatives, in presence of tertbutyl alcohol, afforded the corresponding [18F]‐3‐[(2‐fluorophenyl)methyl]‐3,5,6,7,8,8a‐hexahydro‐7,7,8a‐trimethyl‐[3S‐(3α,6α,8α,8αβ)]‐6,8‐methano‐2H‐ 1,4‐benzoxazin‐2‐one derivatives (4a, b) without affecting the orientation of diastereofacial discrimination. Deprotection of the derivatives 4a,b yielded 6‐[18F]fluoro‐L‐DOPA (e.e. > 90%, 3% radiochemical yield (EOB), total synthesis time 125 min, specific activity > 2000 mCi/μmol). Direct deprotection/reduction of the compounds 3a,b provides the enantiomeric mixture of 6‐[18F]fluoro‐D,L‐DOPA (10–12% radiochemical yield) and, after chiral separation, 6‐[18F]fluoro‐L‐DOPA (e.e. 98%, 4–5% radiochemical yield). A “cold” enantioselective synthesis of 6‐fluoro‐L‐DOPA has been effected with total chemical yield 15% (e.e. 93.4%).
Synthesis of [8‐14C]‐2,6‐dichloro‐9H‐purine, a radiolabelled precursor for 14C‐nucleosides
Authors: Valsborg Jacob S. , Knutsen Lars J. S. , Lundt Inge , Foged Christian 
Published: October 2006

AbstractThe synthesis of [8‐14C]‐2,6‐dichloro‐9H‐purine (2), a radiolabelled precursor for preparing 14C‐labelled nucleosides, is described. Triethyl[14C]orthoformate was reacted with 4,5‐diamino‐2,6‐dichloropyrimidine (1) in acetonitrile at 90°C with methanesulfonic acid as catalyst to generate 2 in 84% radiochemical yield. Reaction of 2 with 1‐O‐acetyl‐2,3,5‐tri‐O‐benzoyl‐D‐ribofuranose produced [8‐14C]‐9‐(2,3,5‐tri‐O‐benzoyl‐β‐D‐ribofuranosyl)‐2,6‐dichloropurine (3) in 86% yield. The radiochemical purity of 3 was higher than 98% with a specific activity of 36 mCi/mmol. This method has general application to 14C‐labelling of purines in drug development.
An efficient synthesis of 1‐[13C]‐bromobenze
Authors: Geletneky Christian , Balzer Hartmut , Bock Willi , Berger Stefan 
Published: October 2006

AbstractVarious routes to functionalized benzenes labelled in position 1 were compared. 1‐[13C]‐Bromobenzene has been synthesized in 7 steps with an overall yield of 5.4% from [13C]‐BaCO3, by optimizing the direct transformation of p‐nitrophenol into bromobenzene.
Preparation and investigation of [14C]padimate‐O and [14C]N‐nitroso‐N‐nor‐padimate‐O
Authors: Lewin Anita H. , Fudala Louise 
Published: October 2006

AbstractCarbonation of the aryl lithium obtained from p‐N,N(dimethylamino)bromobenzene with carbon‐14 labeled carbon dioxide, followed by esterification gave [CO2‐14C]p‐N,N(dimethylamino)benzoate 2‐ethylhexyl ester (Padimate‐O). This material underwent slow decomposition to [14C]N‐nor‐Padimate‐O and [14C]N‐formyl‐N‐nor‐Padimate‐O. Nitrosation of [14C]Padimate‐O with sodium nitrite afforded [14C]N‐nitroso‐N‐nor‐Padimate‐O.
Synthesis of tritium‐labelled 5‐chloro‐2′,3′‐dideoxy‐3′‐fluorouridine (935u83) ‐ a selective anti‐HIV agent
Authors: Hill John A. , Bankston Donald D. 
Published: October 2006

Abstract[5′‐3H]‐5‐Chloro‐2′,3′‐diodeoxy‐3′‐fluorouridine (1; R = [3H]) was prepared at a specific activity of 10.2 Ci/mmol suitable for development of a radioimmunoassay procedure. The synthetic sequence employed controlled oxidation of unlabelled 1 to the 5′‐aldehyde (2), isolation as the imidazolidine adduct (3), regeneration of the free aldehyde, reduction with [3H]NaBH4, and purification by preparative TLC. The radiochemical purity was 98.0%.
Carbon‐11 labeling of a potent, nonpeptide, at1‐selective angiotensin‐II receptor antagonist: MK‐996
Authors: Mathews William B. , Burns H. Donald , Dannals Robert F. , Ravert Hayden T. , Naylor Elizabeth M. 
Published: October 2006

Abstract[α‐11C]Benzoyl chloride was synthesized and purified by normal phase HPLC. [11C]MK‐996 ([11C]N‐[[4′[(2‐ethyl‐5,7‐dimethyl‐3H‐imidazo [4,5‐b]pyridin‐3‐yl)methyl][1,1′‐biphenyl]‐2‐yl]sulfonyl]‐benzamide), a potent and selective ligand for the AT1 receptor, was prepared by N‐benzoylation of L‐159,221 with [α‐11C]benzoyl chloride in tetrahydrofuran using lithium bis(trimethylsilyl)amide as a base. The radiotracer was purified by semi‐preparative reverse‐phase HPLC. The average specific activity was 1162 mCi/μmol calculated at end‐of‐synthesis (EOS). The average time of synthesis including formulation was 30 minutes.
Hemisynthesis of [3′‐14C]‐Taxotere®
Authors: de Suzzoni S. , Boullais C. , Vandais A. , Noel J. P. 
Published: October 2006

AbstractA new route to semisynthetic Taxotère®, 1. is described using the mixed anhydride obtained from 2,4,6‐trichlorobenzoyl chloride and [3‐14C]‐cinnamic acid 6, for the esterification of 7,10‐O‐diTroc‐10‐deacetylbaccatin III, 4. Hydroxyamination on the unsatured C‐2′,3′,deprotection of the C‐7,10‐Troc groups of the ester 7 gave Taxotère® 1. [3′‐14C]Taxotère® 9 (specific activity: 50 mCi/mmol) was obtained from [3‐14C]‐cinnamic acid 5 with a 5% yield.
Synthesis and purification of 13C labelled xanthine derivatives
Authors: Boukraa M. S. , Deruaz D. , Bannier A. , Desage M. , Brazier J. L. 
Published: October 2006

Abstract3‐[Methyl‐13C]xanthine, 7‐[Methyl‐13C]xanthe, 1,3‐[Dimethyl‐13C2]xanthine (theophylline‐1,3‐[13CH3]2), 1,7‐[Dimethyl‐13C2]xanthine (paraxanthine‐1,7‐[13CH3]2), and 3,7‐[Dimethyl‐13C2]xanthine (theobromine‐3,7‐[13CH3]2) were synthesized by nucleophilic substitution reaction (SN2) from xanthine (X) and iodomethane‐[13C]. The 3‐isobutylparaxanthine‐7‐[13CH3] was prepared from 3‐isobutyl‐1‐methylxanthine (IBMX). The compounds were purified by reverse phase semipreparative liquid chromatography and their chemical structure and purity verified by GC‐MS.
Synthesis of non ‐ carrier added [N ‐ methyl ‐ 11C] roxithromycine
Authors: Barre L. , Lasne M. C. , Charbonneau P. 
Published: October 2006

AbstractRoxithromycine, a new macrolide, was labelled with [11C]CH3I in a good radiochemical yield (40‐45%)and high specific activities (500‐550mCi/μmol). This antibiotic may be useful for detecting pulmonar or cerebral infection foci using positron emission tomography.
Preparation of riboflavin specifically labeled in the 5′‐hydroxymethyl terminus using a vitamin B2‐aldehyde‐forming enzyme from Schizophyllum commune
Authors: Kekelidze Tea N. , Edmondson Dale E. , McCormick Donald B. 
Published: October 2006

AbstractA method is described for synthesis of riboflavin selectively labeled in the hydrogens at the 5′‐hydroxymethyl position. In this method, a vitamin B2‐aldehyde‐forming enzyme from Schizophyllum commune is used to specifically and completely oxidize the 5′‐hydroxymethyl of riboflavin to the 5′‐aldehyde. This reaction is monitored spectrophotometrically by the reduction of 2,6‐dichlorophenolindophenol at 600 nm. Appearance of aldehyde product was directly quantitated by reverse‐phase high‐performance liquid chromatography. Product is extracted from the incubation mixture by phenol after saturation with (NH4)2SO4 and then further purified by benzyl alcohol extraction. The 5′‐aldehyde is reduced with appropriately labeled sodium borohydride to yield the vitamin specifically labeled in the 5′‐hydroxymethyl group.
Synthesis of isotopically labelled pyridoindolone 5‐HT3 receptor antagonists (1)
Authors: Prakash Shimoga R , Cable Karl M , Correa Itzela D , Fellows Lan , Montgomery Stephen , Newman John J , Waterhouse Lan , Wells Guy N , Sutherland Derek R 
Published: October 2006

AbstractSyntheses of labelled versions of 5‐HT3 receptor antagonists, Alosetron and Lurosetron, are described. [14C]Alosetron was prepared by routes utilizing either Fischer indolisation of an amidohydrazine or palladium‐mediated cyclisation of an aryl enaminone as key steps. 2H and 13C versions of Alosetron were prepared from suitably labelled imidazoles. Lurosetron was labelled in either the methylene bridge carbon or carbonyl carbon, using 14C‐labelled paraformaldehyde or phosgene, respectively.
Very high isotope incorporation in the C‐1 position of glucose by exchange with deuterium or tritium gas
Authors: Long Mervyn A. , Morimoto Hiromi , Williams Philip G. 
Published: October 2006

AbstractThe experimental conditions which control the exchange from deuterium or tritium gas into the C‐1 proton position of glucose in aqueous solution have been studied in detail, with a view to determining the factors which maximize exchange into glucose, but minimize exchange into the solvent water. The favoured conditions for producing glucose with close to 100% isotope labelling in the C‐1 position, and with negligible formation of labelled byproducts, were a reaction time of 6 to 8 hours, a temperature of 60 °C, and a pH of 7 or higher. Pd/BaSO4 was the preferred catalyst and slow pre‐addition of the deuterium or tritium gas to the catalyst bed was essential to maximize the subsequent isotope exchange into the substrate.
Synthesis of disodium [benzene‐U‐14C]‐(4‐chlorophenylthio)methylenediphosphonate, [benzene‐U‐14C]‐tiludronate
Authors: Burgos Alain , Ellames George J. 
Published: October 2006

AbstractDisodium [benzene‐U‐14C]‐(4‐chlorophenylthio)methylenediphosphonate, [benzene‐14C]‐Tiludronate, 2, has been prepared in six steps from [benzene‐U‐14C]‐acetanilide in an overall radiochemical yield of 41%. A key step in this transformation was the efficient conversion of [U‐14C]‐4‐chloroaniline to [benzene‐U‐14C]‐4‐chlorophenylthiocyanate, 5, in 83% yield by treatment of the corresponding diazonium salt, 9, with iron (III) thiocyanate. It should be noted that formation of the isomeric [benzene‐U‐14C]‐4‐chlorophenylisothiocyanate, 11, as a byproduct, was observed in only ∼ 1% yield.
Preparation Microbiologique Du 2‐CETO‐3‐Desoxy‐D‐Gluconate 1‐14C ou U‐14C
Authors: Pouyssegur J. 
Published: October 2006

AbstractA E. Coli K 12 mutant having lost 2‐keto‐3‐desoxy‐gluconate kinase activity is unable to utilize glucuronate as a unique carbon source. However, this strain is able to partially convert glucuronate into KDG in resting cells conditions reported here.A method is described making it possible to produce 1‐14C‐KDG or U‐14C‐KDG when the kinase cells metabolise 6‐14C or U‐14C‐D‐glucuronate. The radioactive KDG accumulated in the incubation medium has been purified thanks to a biological specific method followed by chromatography on anionic resin. The yield of the purified KDG from the hexuronate is about 20%. According to chromatographic criteria and specific conversion by KDG‐kinase, the product obtained has been authenticated as true KDG.
The synthesis of 14C‐eugenol and isoeugenol labeled in the methoxy position
Authors: Rabinowitz J. L. , Weinberg J. E. , Gennaro A. R. , Zanger M. 
Published: October 2006

AbstractMethylation under pressure of o‐allyloxyphenol with 14C‐metheyl iodide was successfully used for the synthesis of 14C‐eugenol and isoeugenol labeled in the methoxy position. Eugenol and isoeugenol are important compounds in the practice of dentistry.
Synthesis of 2‐pyrrolidinone‐5‐14C
Authors: Villani A. J. , Mendelson W. L. , Blackburn D. W. 
Published: October 2006

AbstractA convenient synthesis of the pharmacological intermediate 2‐pyrrolidione‐5‐14C, was developed using potassium cyanide 14C as starting material. Potassim cyanide‐14C was converted to 2‐pyrrolidinone‐5‐14C in an overall 56% radiochemical yield.
Synthesis of labeled anti‐inflammatory agents
Authors: Hafferl W. , Hary A. 
Published: October 2006

AbstractThe synthesis of the anti‐ inflammatory agents d‐2‐(6′‐methoxy‐2′‐naphthyl)‐propionic acid and 1‐2‐(6′‐methoxy‐2′‐naphthyl)‐propanol labeled with 14C and 3H is described.
Preparation of high specific activity DL‐tryptophan‐2, 3‐T and its resolution to l‐tryptophan‐2, 3‐T
Authors: Ramamurthy T. V. , Pichat L. 
Published: October 2006

AbstractDL‐Tryptophan‐2, 3‐T of high specific activity was obtained by reducing a suitable precursor with T2 gas. It was resolved also into L‐Tryptophan‐2, 3‐T by using the enzyme carboxypeptidase. The optical purity of L‐Tryptophan‐2, 3‐T was greater than 99% and the specific activity was 15 Ci/mM.
Synthsis of meleylacetoacetate‐214C, maleylacetone‐114C and homogentisic acid γ‐lactone‐α‐14C. 1
Authors: Seltzer S. 
Published: October 2006

AbstractSyntheses of the title compounds were accomplished by a sequence of reactions involving Friedel Crafts 14C‐acetylation of p‐dimethoxybenze, willgerodt rearrangement of 2, 5‐dimethoxyacetophenone‐carbonyl‐14C (I) to 2, 5‐dimethoxyphenylactic acid‐a14C (II), followed by hydrolysis to homogentisic acid γ‐lactone‐α‐14C(III). Oxygenation of the lactone by an osygenaser from animal liver provided a solution of maleyacetoacetate‐2‐14C (IV). Decarboxylation of this matrial leads to a solution of maleylacetone‐1‐14C (V). Funaruylactone‐1‐14C (VT) can be obtained from V by silver ion‐catalysed cis‐trans isomerization.
A high yield photochemical preparation of 4 ‐ nitrocatechol‐ UL ‐14C
Authors: Norris F. A. , Still G. G. 
Published: October 2006

Abstract4‐Nitrocatechol ‐UL‐ 14C was synthesized in 48, 9% yield by the photolysis of 4‐nitrophenol ‐UL‐ 14C in aqueous hydrogen peroxide.
Quality control of radioactive products for patient administration at the national institutes of health
Authors: Vacca Patricia C. , Farkas Raymond J. , Semler Mark O. 
Published: October 2006

AbstractThis paper describes the quality control procedure for radioactive materials destined for patient use at the National Institutes of Health. The Radiopharmaceutical Section is responsible for attesting to pharmaceutical quality, while the Radiation Safety Section performs per‐unit‐volume assays and radionuclidic purity checks on these materials. Types and examples of product error are presented as well as statistical data on essay discrepancies. The frequency of error during the past ten years indicates the necessity of continued quality control testing of all radioactive materials, regardless of source of supply and prior administration to patients.
Evidence of a disturbance of the hypothalamic‐pltuitary‐adrenal axis in polycystic ovary syndrome: effect of naloxone
Authors: Lanzone Antonio , Guido Maurlzlo , Ciampelli Mario , Fulghesu Anna Maria , Pavone Virginia , Proto Caterina , Caruso Alessandro , Mancuso Salvatore 
Published: October 2006

SummaryDESIGN There are conflicting data on hypothalamic‐pituitary‐adrenal (HPA) axis function in women with polycystic ovary syndrome (PCOS). We have evaluated the HPA axis responses to naloxone in patients with PCOS compared to control subjects.PATIENTS Twenty PCOS patients and 10 control women participated in the study.MEASUREMENTS On days 5–6 Of a spontaneous or progestin induced cycle each patient received an intravenous bolus (5 mg) of naloxone (time 0 min), followed by a 2‐mg naloxone infusion In 100 ml of 0.9% saline over one hour. Samples were collected at −30, 0, 15, 30, 60, 90 and 120 minutes. ACTH and cortisol levels were measured in all plasma samples.RESULTS PCOS patients showed significantly greater response than controls to naloxone of ACTH (peak value 261 vs 172% of basal value) and cortisol (peak value 237 vs 165% of basal value); also, ACTH and cortisol incremental areas were higher In PCOS patients (P < 0.05 and P < 0.04 respectively).The cortisol/ACTH ratio of AUCs percentage increase was found to be near unity for all patients without significant difference between PCOS and control groups, suggesting a direct correspondence between ACTH circulating levels and adrenal cortisol production.CONCLUSIONS Polycystic ovary syndrome patients showed a hypothalamic‐pituitary‐adrenal axis hyper‐responsiveness to naloxone infusion compared with control subjects. These data support the hypothesis that this disturbance could be central in origin.
Phenotypic evolution of classic 21‐hydroxylase deficiency
Authors: Hoffman William H. , Shln Myung Y. , Donohoue Patricia A. , Helman Sandra W. , Brown Stephanle L. , Rosculet George , Mahesh Virendra B. 
Published: October 2006

SummaryWe describe a female patient who was diagnosed and treated at birth for a classic form of salt‐losing congenital adrenal hyperplasia. At 17 years of age, against medical advice, she discontinued both mineralocorticoid and glucocorticoid replacement with no resulting clinical symptoms other than the occurrence of amenorrhoea. Steroid metabolites revealed significant abnormalities of the renin‐angiotensin‐aldosterone axis, as well as of pituitary‐adrenal function. Analysis of our patient's DNA showed only one deleterious CYP21 mutation, an intron 2 base pair change activating a cryptic splice site. We speculate that expression of this patlent's CYP21 genes may be altered by the effects of ageing or by changes in the steroid milieu.
Information sources used by New South Wales cancer clinicians: a qualitative study
Authors: Tan E. L. , Stark H. , Lowinger J. S. , Ringland C. , Ward R. , Pearson S.‐A. 
Published: October 2006

AbstractBackground: This study identified (i) information sources used by cancer clinicians to guide pharmacological treatments, (ii) utilization of, and opinions about, online information sources and (iii) clinicians’ ability to access a specific cancer treatment protocol (escalated bleomycin, etiposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP) for Hodgkin’s Lymphoma). The work was carried out before activation of the Cancer Institute New South Wales Standard Cancer Treatment (CI‐SCaT) programme.Methods: We conducted semistructured interviews with a purposeful sample of senior and junior doctors, nurses and pharmacists treating adult cancer patients (n = 32) in eight New South Wales public hospitals.Results: Information seeking processes are context specific and vary from clinician to clinician and ward to ward. Clinicians use human, electronic and printed information sources at, or close to, the point of patient care; however, experienced colleagues are preferred where information is needed quickly or in unfamiliar clinical situations. Barriers to using online cancer information are environmental (hardware, connection speeds, time), personal (poor computer literacy and lack of awareness of appropriate sites) and economic (costs of journal subscriptions). Just over half of participants were able to locate a specific cancer protocol and none of these protocols was fully consistent with CI‐SCaT recommendations.Conclusion: There is no standardized approach to the pharmacological treatment of cancer patients in this sample of New South Wales clinicians. CI‐SCaT will fill a gap with respect to standardizing oncology treatment. However, to ensure maximal CI‐SCaT uptake, implementation plans should harness positive behavioural influences and attempt to modify the negative forces that act on hospital clinicians in their day‐to‐day work.